1[1]Margaglione M,Colaizzo D,DAndrea G,et al.Genetic modulation of oral anticoagulation with warfarin[J].Thromb Haemost,2000,84(5):775-778.
2[2]Higashi MK,Veenstra DL,Kondo LM,et al.Association between CYP2C9 genetic variations anticoagulation-related outcomes during warfarin therapy[J].JAMA,2002,287 (13):1691-1698.
3[3]Adcock DM,koftan C,Crisan D,et al.Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation[J].Arch Pathol Lab Med,2004,128 (12):1360-1363.
4[4]Freeman BD,Zehnbauer BA,McGrath S,et al.Cytochrome P450 polymorphisms are associated with reduced warfarin dose[J].Surgery,2000,128(2):281-285.
5[5]Wadelius M,Sorlin K,Wallerman O,et al.Warfarin sensitivity related to CYP2C9,CYP3A5,ABCB1 (MDR1) and other factors[J].Pharmacogenomics J,2004,4 (1):40-48.
6[6]Montes R,Ruiz de Gaona E,Martinez-Gonzalez MA,et al.The c.-1639G＞A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients[J].Br J Haematol,2006,133 (2),183-187.
7[7]Yuan HY,Chen JJ,Lee MT,et al.A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity[J].Hum Mol Genet,2005,14(13):1745-1751.
8[8]Reitsma PH,van der Heijden JF,Groot AP,et al.A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk[J].PLoS Med,2005,2(10):e312.
9[9]Schalekamp T,Brasse BP,Roijers JF,et al.VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status:interaction between both genotypes affects overanticoagulation[J].Clin Pharmacol Ther,2006,80(1):13-22.
10[10]Lee SC,Ng SS,Oldenburg J,et al.Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population[J].Clin Pharmacol Ther,2006,79(3):197-205.
2Jiang X,Williams KM,Liauw WS,et al.Effect of St.John's wort and ginseng on the pharmacokinetics andpharmacodynamics of warfarin in healthy subjects[J].Br J Clin Pharmacol,2004,57(5):592-599.
4The International Warfarin Pharmacogenetics Consortium. Es- timation of the warfarin dose with clinical and pharmaeogenetic data[J]. N Engl J Med,2009,360(8) :753-764.
